1. Home
  2. PENN vs NAMS Comparison

PENN vs NAMS Comparison

Compare PENN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PENN
  • NAMS
  • Stock Information
  • Founded
  • PENN 1972
  • NAMS 2019
  • Country
  • PENN United States
  • NAMS Netherlands
  • Employees
  • PENN N/A
  • NAMS N/A
  • Industry
  • PENN Hotels/Resorts
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PENN Consumer Discretionary
  • NAMS Health Care
  • Exchange
  • PENN Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • PENN 2.3B
  • NAMS 2.5B
  • IPO Year
  • PENN 1994
  • NAMS N/A
  • Fundamental
  • Price
  • PENN $17.05
  • NAMS $17.96
  • Analyst Decision
  • PENN Buy
  • NAMS Strong Buy
  • Analyst Count
  • PENN 19
  • NAMS 8
  • Target Price
  • PENN $23.03
  • NAMS $42.88
  • AVG Volume (30 Days)
  • PENN 4.3M
  • NAMS 893.6K
  • Earning Date
  • PENN 08-07-2025
  • NAMS 08-06-2025
  • Dividend Yield
  • PENN N/A
  • NAMS N/A
  • EPS Growth
  • PENN N/A
  • NAMS N/A
  • EPS
  • PENN N/A
  • NAMS N/A
  • Revenue
  • PENN $6,643,700,000.00
  • NAMS $47,140,000.00
  • Revenue This Year
  • PENN $7.93
  • NAMS N/A
  • Revenue Next Year
  • PENN $5.59
  • NAMS N/A
  • P/E Ratio
  • PENN N/A
  • NAMS N/A
  • Revenue Growth
  • PENN 5.51
  • NAMS 586.97
  • 52 Week Low
  • PENN $13.25
  • NAMS $14.06
  • 52 Week High
  • PENN $23.08
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • PENN 60.16
  • NAMS 42.30
  • Support Level
  • PENN $15.58
  • NAMS $20.06
  • Resistance Level
  • PENN $16.77
  • NAMS $21.91
  • Average True Range (ATR)
  • PENN 0.62
  • NAMS 1.41
  • MACD
  • PENN 0.15
  • NAMS -0.20
  • Stochastic Oscillator
  • PENN 82.68
  • NAMS 4.45

About PENN PENN Entertainment Inc.

Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: